Zhitong Finance App News, Lepu Biotech (02157.HK) issued an announcement at the 2026 Annual Meeting of the European Society of Medical Oncology (ESMO Conference 2026): (1) The positive research results of CMG901 in second-line and post-line (2L+) Claudin 18.2 positive phase III clinical trials for advanced/metastatic gastroesophageal cancer (GEC) were selected in the Major Research Summary (LBA) and will present selected papers at the Chairman's seminar; (2) MRG007 (a type of treatment of colorectal cancer (CRC)) The positive results of the phase I clinical study of the potential best-in-class CDH17 targeting antibody drug conjugate (ADC) drug candidate) were selected for the LBA and will be reported quickly orally at the conference;

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.